Literature DB >> 8152253

Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia.

F E Katz1, R C Lovering, L A Bradley, K P Rigley, D Brown, F Cotter, J M Chessells, R J Levinsky, C Kinnon.   

Abstract

The gene which causes X-linked agammaglobulinemia, btk, has recently been identified as a cytoplasmic tyrosine kinase expressed almost exclusively in B cells, and at all stages of B-cell differentiation. To assess the possibility of involvement of this gene in childhood B-cell malignancies, cells from 23 pediatric patients with B-cell acute lymphoblastic leukemia were examined for expression and alteration of the Btk protein and also for mutations in the btk gene. Btk proteins, similar in both molecular weight and quantity to those seen in unaffected individuals, were detected in whole cell lysates from the blasts of 12/12 patients indicating that no abnormal protein was present. cDNAs from the leukemic blasts of all 23 patients were screened with specific primers covering the coding region of the btk cDNA for mutations using single strand conformation polymorphism (SSCP) analysis. No mutations were found but a nucleotide polymorphism was identified in 4/23 patients at the 3' end of btk. Although the sample size in this study was relatively small, these data suggest that btk does not appear to play a critical role in childhood B-cell leukemias.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8152253

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.

Authors:  Ajoy Dias; Saad J Kenderian; Gustavo F Westin; Mark R Litzow
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

2.  Inactivation of Btk by insertion of lacZ reveals defects in B cell development only past the pre-B cell stage.

Authors:  R W Hendriks; M F de Bruijn; A Maas; G M Dingjan; A Karis; F Grosveld
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

3.  Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.

Authors:  Ekaterina Kim; Christian Hurtz; Stefan Koehrer; Zhiqiang Wang; Sriram Balasubramanian; Betty Y Chang; Markus Müschen; R Eric Davis; Jan A Burger
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

4.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 5.  A comprehensive review of protein kinase inhibitors for cancer therapy.

Authors:  Radhamani Kannaiyan; Daruka Mahadevan
Journal:  Expert Rev Anticancer Ther       Date:  2018-10-09       Impact factor: 4.512

Review 6.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.

Authors:  Aqu Alu; Hong Lei; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2022-10-01       Impact factor: 23.168

Review 7.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.